Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin, or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients

    November 2020 in “ Research Square (Research Square)
    Flavio Cadegiani, Andy Goren, Carlos Gustavo Wambier, John McCoy
    Image

    Preprint — not peer reviewed. This was posted to a preprint server or data repository. It has not been through a journal's review process, and its findings may change or not hold up.

    Studysummary In this study, early treatment with nitazoxanide, ivermectin, or hydroxychloroquine, combined with azithromycin, was associated with reduced hospitalizations, respiratory complications, and deaths in early-stage COVID-19 patients compared to untreated controls.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    7 / 7 results